Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.66 |
| ▸ | F3 | P13726 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | MDH2 | P40926 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30906941 | 1.00 | F7 (0.66) | F7F3CYP1A2ALDH1A1HPGD | |
| SCHEMBL613332 | 0.90 | F7 (0.74) | F7F3ALDH1A1HPGDMEN1 | |
| SCHEMBL30392504 | 0.90 | F7 (0.74) | F7F3ALDH1A1HPGDMEN1 | |
| Ammonia Solution, Strong SCHEMBL4556453 | 0.88 | F7 (0.72) | F7F3ALDH1A1HPGDMEN1 | |
| SCHEMBL398364 | 0.87 | F7 (0.81) | F7F3CYP1A2ALDH1A1HPGD | |
| SCHEMBL4334729 | 0.84 | F7 (0.51) | F7F3CYP1A2ALDH1A1HPGD | |
| SCHEMBL18589525 | 0.82 | CYP1A2 (0.64) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL7162254 | 0.82 | NR4A2 (0.59) | F7F3ALDH1A1KMT2ANR4A2 | |
| SCHEMBL12786892 | 0.81 | CYP1A2 (0.62) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL4452877 | 0.81 | KDM4E (0.77) | CYP1A2ALDH1A1HPGDMEN1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59137481-A | — | — | None | — | — | JP | disclosed |
| JP-59013777-A | — | — | None | — | — | JP | disclosed |
| JP-59010580-A | — | — | None | — | — | JP | disclosed |
| JP-59029685-A | — | — | None | — | — | JP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017198196-A1 | QUINOLINE DERIVATIVE HAVING ANTI-TUMOR ACTIVITY | 王子厚 | 2017-11-23 | — | — | WO | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| JP-S59137481-A | 7-DIAZABICYCLOALKANE-SUBSTITUTED-4-OXO-1,4-DIHYDRO- QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-08-07 | — | — | JP | disclosed |
| JP-S5929685-A | 7-SUBSTITUTED PHENYLPIPERAZINO-4-OXO-1,4-DIHYDROQUINOLINE- 3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-02-16 | — | — | JP | disclosed |
| JP-S5913777-A | 7-HOMOPIPERAZINE-SUBSTITUTED-4-OXO-1,4-DIHYDRO-QUINOLINE-3- CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-01-24 | — | — | JP | disclosed |
| JP-S5910580-A | 7-PHENYL-SUBSTITUTED PIPERAZINO-4-OXO-1,4- DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-01-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | F7 4811/4885F3 3651/4885CYP1A2 2537/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | F7 4811/4885F3 3651/4885CYP1A2 2537/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | F7 4811/4885F3 3651/4885CYP1A2 2537/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | F7 4683/4885F3 3663/4885CYP1A2 3682/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | F7 4408/4885F3 2599/4885CYP1A2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.